Preventative Effect of Topical Rebamipide Against Corneal Epithelium Disorders Caused by Diclofenac Sodium
<b><i>Purpose:</i></b> This study aimed to investigate the relationship between diclofenac sodium ophthalmic solution (DFNa) and corneal epithelial cell damage and to evaluate the preventive effect of rebamipide (RBM) on it. <b><i>Methods:</i></b> DFNa, DFNa/preservative-free (PF), or 0.5% chlorobutanol (CB) solution was instilled into the conjunctival sac of a normal rabbit eye, and corneal resistance measurement (using a corneal resistance device [CRD]) was performed 120 min after the end of instillation. Then, fluorescent staining (FL), corneal tissue staining (hematoxylin and eosin [H&E]), and immunostaining (zona occlusion-1) were performed (RBM-untreated group). However, RBM was instilled into the eyes of another group of normal rabbits, followed by each of the solutions; 120 min after the end of instillation, all evaluations were performed for this group (RBM treatment group). <b><i>Results:</i></b> Using the CRD method, in the RBM-untreated group, corneal resistance (CR; %) was found to be significantly reduced in DFNa (79.9 ± 19.4%), DFNa/PF (89.1 ± 17.3%), and 0.5% CB (83.8 ± 10.6%). In addition, DFNa and 0.5% CB solutions showed positive staining in the FL staining method. In the H&E staining method, some clear voids were observed in the outermost layer of the cornea using DFNa and 0.5% CB solutions. However, corneal epithelial damage was suppressed in the RBM treatment group. ZO-1 immunostaining in DFNa and 0.5% CB solutions revealed discontinuous localization of ZO-1 at the cell periphery. <b><i>Conclusions:</i></b> RBM eye drops were effective in preventing corneal epithelial damage caused by DFNa eye drops, and CB was considered to be the main causative agent of this damage.
Authors
- Masamichi Fukuda (ORCID: https://orcid.org/0000-0002-5593-0067)
- Takayoshi Masuoka (ORCID: https://orcid.org/0000-0002-1689-8762)
- Hiroshi Sasaki (ORCID: https://orcid.org/0000-0002-6458-5330)
- Shun Takeda (ORCID: https://orcid.org/0000-0003-0065-4752)
- Yu Sasaki (ORCID: https://orcid.org/0000-0002-3939-9480)
- Eri Kubo (ORCID: https://orcid.org/0000-0001-6789-9311)
- Takeshi Kiyoi (ORCID: https://orcid.org/0000-0002-0842-1614)
Institutions
- Kanazawa Medical University Hospital (JP)
Publication Details
- Journal
- Journal of Ocular Pharmacology and Therapeutics
- Published
- 2024-09-01
- DOI
- https://doi.org/10.1089/jop.2024.0025
- Citations
- 1
- Primary Topic
- Ocular Surface and Contact Lens
- Type
- article
- Field-Weighted Citation Impact
- 0.54